These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 27716615)

  • 1. PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.
    Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; de Vos L; Franzen A; Schröck F; Bootz F; Kristiansen G; Schröck A; Dietrich D
    Oncotarget; 2016 Nov; 7(46):75827-75838. PubMed ID: 27716615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract.
    Uhl B; Dietrich D; Branchi V; Semaan A; Schaefer P; Gevensleben H; Rostamzadeh B; Lingohr P; Schäfer N; Kalff JC; Kristiansen G; Matthaei H
    PLoS One; 2016; 11(10):e0165769. PubMed ID: 27798672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.
    Sailer V; Gevensleben H; Dietrich J; Goltz D; Kristiansen G; Bootz F; Dietrich D
    PLoS One; 2017; 12(6):e0179412. PubMed ID: 28617833
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
    Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas.
    Sailer V; Charpentier A; Dietrich J; Vogt TJ; Franzen A; Bootz F; Dietrich D; Schroeck A
    PLoS One; 2018; 13(2):e0192742. PubMed ID: 29425237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.
    Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A
    Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients.
    Dietrich D; Weider S; de Vos L; Vogt TJ; Färber M; Zarbl R; Hunecke A; Glosch AK; Gabrielpillai J; Bootz F; Bauernfeind FG; Kramer FJ; Kristiansen G; Brossart P; Strieth S; Franzen A
    Clin Chem; 2023 Sep; 69(9):1050-1061. PubMed ID: 37477541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
    Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
    PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.
    Virani S; Bellile E; Bradford CR; Carey TE; Chepeha DB; Colacino JA; Helman JI; McHugh JB; Peterson LA; Sartor MA; Taylor JM; Walline HM; Wolf GT; Rozek LS
    BMC Cancer; 2015 Oct; 15():825. PubMed ID: 26518708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients.
    Goltz D; Gevensleben H; Dietrich J; Schroeck F; de Vos L; Droege F; Kristiansen G; Schroeck A; Landsberg J; Bootz F; Dietrich D
    Oncotarget; 2017 Jun; 8(25):41011-41020. PubMed ID: 28487502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of gene methylation in surgical margin imprints with locoregional recurrence in head and neck squamous cell carcinoma.
    Hayashi M; Wu G; Roh JL; Chang X; Li X; Ahn J; Goldsmith M; Khan Z; Bishop J; Zhang Z; Zhou XC; Richmon J; Agrawal N; Koch WM
    Cancer; 2015 Jun; 121(12):1957-65. PubMed ID: 25773145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
    Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
    Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomeric Repeat-Containing RNAs (TERRA) Decrease in Squamous Cell Carcinoma of the Head and Neck Is Associated with Worsened Clinical Outcome.
    Vitelli V; Falvo P; G Nergadze S; Santagostino M; Khoriauli L; Pellanda P; Bertino G; Occhini A; Benazzo M; Morbini P; Paulli M; Porta C; Giulotto E
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.
    Kostareli E; Hielscher T; Zucknick M; Baboci L; Wichmann G; Holzinger D; Mücke O; Pawlita M; Del Mistro A; Boscolo-Rizzo P; Da Mosto MC; Tirelli G; Plinkert P; Dietz A; Plass C; Weichenhan D; Hess J
    Epigenetics; 2016; 11(1):61-73. PubMed ID: 26786582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
    Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
    Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the methylation profile of exfoliated cell samples from patients with head and neck squamous cell carcinoma.
    Longo AL; Rettori MM; de Carvalho AC; Kowalski LP; Carvalho AL; Vettore AL
    Head Neck; 2014 May; 36(5):631-7. PubMed ID: 23595968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature.
    Chen SJ; Liu H; Liao CT; Huang PJ; Huang Y; Hsu A; Tang P; Chang YS; Chen HC; Yen TC
    Oncotarget; 2015 Jul; 6(20):18066-80. PubMed ID: 25980437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
    Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
    Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.